USCA RIA’s Teva Pharmaceuticals TEVA Stock Holding History

USCA RIA’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$1.27M	Sell	128,300 -1,700	-1%	-$18K	0.08%	274
2021 Q1	$1.5M	Sell	130,000 -2,272	-2%	-$26.1K	0.1%	254
2020 Q4	$1.28M	Sell	132,272 -11,762	-8%	-$113K	0.09%	211
2020 Q3	$1.3M	Hold	144,034	–	–	0.1%	180
2020 Q2	$1.78M	Sell	144,034 -1,919	-1%	-$21.7K	0.16%	133
2020 Q1	$1.31M	Buy	145,953 +13,850	+10%	+$142K	0.15%	146
2019 Q4	$1.29M	Sell	132,103 -12,640	-9%	-$113K	0.12%	224
2019 Q3	$996K	Buy	144,743 +1,802	+1%	+$13.8K	0.1%	235
2019 Q2	$1.32M	Buy	+142,941	New	+$1.72M	0.13%	198

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

USCA RIA's TEVA Position: Q2 2021 in Review

USCA RIA reduced its Teva Pharmaceuticals (TEVA) stake by 1.3% in Q2 2021, selling an estimated $18K and leaving 128,300 shares worth $1.27M. The position accounts for 0.08% of the portfolio, ranked #274.

USCA RIA first reported a position in TEVA in Q2 2019 and has held it in 9 quarters since. The position peaked at $1.78M in Q2 2020. 440 funds tracked by Wall St. Rank hold TEVA as of Q2 2021.

USCA RIA held 128,300 shares of Teva Pharmaceuticals worth $1.27M as of Q2 2021.
USCA RIA sold 1,700 Teva Pharmaceuticals shares in Q2 2021, an estimated $18K.
Teva Pharmaceuticals made up 0.08% of USCA RIA's portfolio in Q2 2021, its #274 holding.
USCA RIA first reported a position in Teva Pharmaceuticals in Q2 2019 and has held it in 9 quarters since.
USCA RIA's Teva Pharmaceuticals position peaked at $1.78M in Q2 2020.
440 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2021.

Based on USCA RIA's 13F filing for Q2 2021, filed 28 Jul 2021.